NCT01537432View on ClinicalTrials.gov

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
DRUG

secukinumab

secukinumab

DRUG

placebo

placebo comparator

Trial Locations (12)

10065

Novartis Investigative Site, New York

14623

Novartis Investigative Site, Rochester

23507

Novartis Investigative Site, Norfolk

27262

Novartis Investigative Site, High Point

35205

Novartis Investigative Site, Birmingham

46256

Novartis Investigative Site, Indianapolis

63117

Novartis Investigative Site, St Louis

75230

Novartis Investigative Site, Dallas

77030

Novartis Investigative Site, Houston

91105

Novartis Investigative Site, Pasadena

08520

Novartis Investigative Site, East Windsor

07044

Novartis Investigative Site, Verona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01537432 - Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients | Biotech Hunter | Biotech Hunter